Barbara Burtness
芭芭拉·伯特尼斯
MD
Professor of Medicine (Medical Oncology); Co-Leader, Developmental Therapeutics Program, Yale Cancer Center医学教授（肿瘤内科）；耶鲁癌症中心发育治疗项目联合负责人
👥Biography 个人简介
Barbara Burtness is a leading medical oncologist at Yale specializing in head and neck cancer. She was a principal investigator on KEYNOTE-048, the landmark trial that established pembrolizumab as first-line standard of care for recurrent/metastatic HNSCC, and has pioneered research into HPV biology and targeted therapy.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
KEYNOTE-048 Pembrolizumab Frontline HNSCC
Served as a key investigator on KEYNOTE-048, which demonstrated that pembrolizumab alone or combined with chemotherapy significantly improved overall survival in recurrent/metastatic HNSCC, changing global first-line treatment standards.
HPV Biology and Biomarker Development
Led research elucidating the distinct biology of HPV-positive versus HPV-negative HNSCC and identifying predictive biomarkers for immunotherapy response, guiding patient selection strategies.
Representative Works 代表性著作
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048)
The Lancet (2019)
Pivotal phase III trial establishing pembrolizumab as first-line standard of care for recurrent/metastatic HNSCC in PD-L1-expressing tumors.
Phase II trial of irinotecan/docetaxel or irinotecan/docetaxel/cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
Annals of Oncology (2014)
Evaluated combination regimens for recurrent HNSCC, contributing to the understanding of cetuximab activity in platinum-refractory disease.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 芭芭拉·伯特尼斯 的研究动态
Follow Barbara Burtness's research updates
留下邮箱，当我们发布与 Barbara Burtness（Yale School of Medicine）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment